Vernal Keratoconjunctivitis Treatment for Children and Adults
Verkazia® is the first and only topical immunomodulator approved for the treatment of vernal keratoconjunctivitis (VKC) for children and adults. VKC is an abnormal ocular condition that mainly affects children and adolescents. Unlike seasonal ocular conjunctivitis, VKC causes severe ocular surface inflammation that may lead to vision loss.
Verkazia is a prescription-only eye drop containing 0.1% cyclosporine—a molecule shown to be effective in the management of VKC. It is uniquely formulated as a cationic ophthalmic emulsion, which improves corneal bioavailability of cyclosporine. Verkazia works by inhibiting T-cell activation along with reducing the level of immune cells and mediators that cause the chronic, severe, and potentially debilitating allergic ocular surface inflammation in those affected by VKC.